Last updated on June 2019

Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest


Brief description of study

ILCOR guidelines recommend Target Temperature Management (TTM) to between 32C and 36C after out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial, TTM at 33C did not confer a survival benefit or improved neurological function, compared to TTM at 36C. A lower target temperature might be beneficial compared with normothermia and early treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study any differences in mortality, neurological function and quality of life between a target temperature of 33C and standard care avoiding fever.

Detailed Study Description

The TTM2 trial is a continuation of the collaboration that resulted in the previous Targeted Temperature Management after out-of-hospital cardiac arrest trial (hereafter: TTM1). With its planned size with it will supersede the TTM1 trial as the largest trial on temperature management as a post-cardiac arrest treatment.

The TTM1 trial (NCT01020916) was a multicenter, multinational, outcome assessor-blinded, parallel group, randomised clinical trial comparing two strict target temperature regimens of 33C and 36C in adult patients, who have sustained return of spontaneous circulation and are unconscious after out-of-hospital cardiac arrest, when admitted to hospital. The trial did not demonstrate any difference in survival until end of trial (Hazard Ratio with a point estimate in favour of 36C of 1.06 (95% confidence interval 0.89-1.28; P=0.51) or neurologic function at six months after the arrest, measured with CPC and mRS.

The planned study is a international, multicenter, parallel group, non-commerical, randomized, superiority trial in which a target temperature om 33C after cardiac arrest will be compared to normothermia and early treatment of fever.

Patients eligible for inclusion will be unconscious adult patients with OHCA of a presumed cardiac cause with stable return of spontaneous circulation. Randomization will be performed by a physician in the emergency department, in the angiography suite or in the intensive care unit via web-based application using permuted blocks with varying sizes, stratified by site. Due to the nature of the intervention, health care staff will not be blinded to the intervention. However, the physicians who will assess outcomes will be blinded to temperature allocation, as will those who perform prognostication.

The intervention period will commence at the time of randomization. Cooling in the hypothermia group will achieved by means of cold fluids and state-of-the-art cooling devices (intravascular or body-surface applied closed loop systems). The initial aim will be to achieve a body temperature of 33.0C. When this has been achieved, the target temperature will be 33C until 28 hours after randomisation. When 28 hours have passed, gradual rewarming at a rate of 1/3C per hour will commence, this will allow 12 hours for rewarming.

In the normothermia arm the aim will be to avoid a temperature greater than or equal to 37.8C using conservative measures. If a single temperature of 37.8 or greater is measured, active cooling with a device should be initiated and maintained until 40 hours after randomization.

All participants will be sedated, mechanically ventilated and hemodynamically supported throughout the intervention period of 40 hours. Participants in both arms who remain comatose after 40h should be kept at a normothermic level (36.5 - 37.7C) until 72h after randomization and active warming should be avoided.

Participants who remain unconscious four days after randomization will be assessed according to a conservative protocol based on the European Resuscitation Council's recommendations for withdrawal of life sustaining therapies.

Follow up will be performed at:

1 month (face-to-face or telephone), Assessment according to the modified Rankin scale (mRS)

6 moths (face-to-face), Assessment according to the mRS-scale. Assessment of health-related quality of life using EQ5D-5L.

Clinical Study Identifier: NCT02908308

Find a site near you

Start Over

Leeuwarden Hospital

Leeuwarden, Netherlands
  Connect »

UPMC-Presbyterian

Pittsburgh, PA United States
  Connect »

The Alfred

Melbourne, Australia
  Connect »

Austin Hospital

Melbourne, Australia
  Connect »

Nepean Hospital

Sydney, Australia
  Connect »

Erasme Hospital

Brussels, Belgium
  Connect »

Hradec Kralove Hospital

Hradec Králové, Czechia
  Connect »

Hradec Kralove Hospital

Hradec Králové, Czechia
  Connect »

Hradec Kralove Hospital

Hradec Králové, Czechia
  Connect »

Hradec Kralove Hospital

Hradec Králové, Czechia
  Connect »

Wellington Hospital

Wellington, New Zealand
  Connect »

Kantonsspital St.Gallen

Saint Gallen, Switzerland
  Connect »